Corcept Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M | $106.0M | $94.2M | $75.4M |
| Depreciation & Amortization | $1.1M | $795.0K | $1.0M | $1.3M | $1.1M | $525.0K | $703.0K | $236.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | $465.0K | $477.0K | $409.0K | — | — | — |
| Stock-Based Compensation | $84.5M | $61.4M | $48.9M | $42.4M | $42.9M | $33.5M | $29.3M | $23.7M |
| Net Cash from Operating Activities | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M | $152.0M | $136.1M | $115.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $211.0K | $2.2M | $139.0K | $413.0K | $469.0K | $1.2M | $1.1M | $298.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $69.8M | $-177.6M | $90.9M | $-114.3M | $136.1M | $-119.3M | $-117.8M | $-90.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $172.9M | $15.7M | $0 | $0 | — | $9.9M | $31.0M | $23.7M |
| Net Cash from Financing Activities | $-220.4M | $-28.3M | $-148.7M | $-17.3M | $-302.6M | $12.2M | $-28.6M | $-14.3M |
| Net Change in Cash | $-7.2M | $-7.9M | $69.2M | $-11.3M | $1.4M | $44.9M | $-10.4M | $10.6M |
| Free Cash Flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M | $150.7M | $135.0M | $115.4M |